JJ

Showing 15 posts of 221 posts found.

janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016
Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …

janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

pfizer_sky

Pfizer sets release date for rival to J&J’s blockbuster drug

October 18, 2016
Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …

4420456374_64a3d7e6aa

Top Ten articles in the Pharma Industry this week

September 16, 2016
Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto

As we come to the end of another week, we’re looking back at an exciting week in the industry; there …

NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis

April 27, 2016
Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation

The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …

cancer

Focus: Ovarian cancer and the case of elusive cure

April 12, 2016
Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer

Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …

jj_sign_on_wall

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016
Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …

janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016
Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …

fda_building

FDA strengthens safety warning for J&J’s diabetes drug Invokana

September 14, 2015
Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes

Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …

Janssen sales follow J&J’s downward trend

July 15, 2015
Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio

Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …

J&J image

J&J to file 10 new key drugs by 2019

May 21, 2015
Sales and Marketing J&J, JJ

Johnson & Johnson says it plans to file 10 new products with regulators between 2015 and 2019 with each having …

FDA image

FDA issues more diabetes drug warnings

May 18, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly

The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …

J&J image

J&J hands over compassionate use reviews to academics

May 7, 2015
Sales and Marketing J&J, JJ, academics, compac, eap, johnson

Johnson & Johnson has struck a ‘first-of-its-kind partnership’ with academic researchers to review requests for compassionate use of its investigational …

J&J image

J&J strong pharma sales can’t offset Q1 losses

April 15, 2015
Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica

Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …

J&J image

IBM partners with J&J, Apple and Medtronics ‘to transform healthcare’

April 14, 2015
Sales and Marketing Apple, J&J, JJ, ibm, medtronics

IT firm IBM has teamed up with pharma giants and tech companies to expand its presence in the health and …

The Gateway to Local Adoption Series

Latest content